Table 4.

Logistic regression analysis for hospitalization, impact of home-based treatment with mabs and/or antivirals adjusted for sex, and age during the overall study period, after the appearance of Alpha strain and mabs availability (January 2021) and after Omicron strain became predominant (December 2021).

	All study periodN of patients=192	January 2021-May 2022N of patients=161	December 2021-May 2022N of patients=121
Hospitalization	**OR (95% CI)	**OR (95% CI)	**OR (95% CI)
mabs and/or antivirals	0.120 (0.043-0.340) p<0.001	0.142 (0.045-0.563) p< 0.001	0.021 (0.002-0.250) p=0.002
mabs	0.140 (0.045-0.436) p<0.001	0.165 (0.048-0.563) p=0.004	0.021 (0.001-0.313) p=0.005
Antivirals	0.069 (0.009-0.551) p=0.012	0.076 (0.009-0.657) p=0.019	0.021 (0.001-0.459) p=0.014

** OR adjusted for age, sex, and CVID diagnosis.